Home > DARE Reviews > Prognostic role of cyclooxygenase-2 in...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies

Review published: 2013.

Bibliographic details: Lee JY, Myung SK, Song YS.  Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecologic Oncology 2013; 129(3): 613-619. [PubMed: 23422504]

Abstract

OBJECTIVE: The aim of this study was to evaluate the prognostic significance of cyclooxygenase-2 (COX-2) on survival in patients with ovarian cancer by using a meta-analysis of observational studies.

METHODS: We searched Pubmed and Embase to retrieve observational studies evaluating the association between COX-2 status and survival in patients with ovarian cancer. Hazards ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were pooled across studies using a random-effects model.

RESULTS: A total of 17 studies were included in this meta-analysis to estimate the association between COX-2 and overall survival (OS), disease-free survival (DFS), response to chemotherapy (RC), and other clinical parameters. In a random-effects meta-analysis of 15 studies, higher COX-2 expression significantly predicted poor OS (death HR, 1.34; 95% CI, 1.05-1.71; I(2)=56.5%). A more prominent association was found between COX-2 expression and poor OS when studies with adjustment for age, stage, and histology were included (death HR, 1.65; 95% CI, 1.25-2.17; I(2)=0%). However, higher COX-2 expression was not significantly associated with poor DFS (recurrence HR, 1.36; 95% CI, 0.79-2.33; I(2)=53.6%) and RC (OR, 1.89; 95% CI, 0.85-4.21; I(2)=17.6%). There was a marginally significant association between COX-2 positivity and several clinical parameters such as age, stage, and histology. The pooled ORs of higher COX-2 expression were 1.75 (95% CI, 1.01-3.04) for advanced stages, 1.34 (95% CI, 0.97-1.85) for old age, and 1.42 (95% CI, 0.98-2.05) for serous cancer in histologic type, respectively.

CONCLUSIONS: The present meta-analysis suggests that higher COX-2 expression may be an independent risk factor for poor OS in patients with ovarian cancer.

Copyright © 2013 Elsevier Inc. All rights reserved.

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2014 University of York.

PMID: 23422504

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...